/C O R R E C T I O N -- Human Longevity, Inc./
SOUTH SAN FRANCISCO, Calif., June 17, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI), a global leader in precision medicine and proactive health, today announced an expansion of its $1 million pledge initiative—this time targeting late-stage pancreatic cancer. Building on the success of its recent prostate cancer commitment, HLI is advancing its mission to detect cancer earlier and improve outcomes for its members by offering financial and clinical support for those members diagnosed with late-stage pancreatic cancer while enrolled in its Executive Health and 100+ Longevity programs.
Driving Innovation in Early Detection
Through its Executive Health Program and 100+ Longevity Programs, Human Longevity has delivered care to over 10,000 members using a comprehensive platform that integrates whole genome sequencing, advanced imaging, and multiplex blood biomarker tracking.
These efforts have enabled the development of what HLI believes to be one of the most advanced early detection algorithms for pancreatic cancer available today, including a new proprietary DNA-based pancreatic cancer screening test.
In most cases, our multi-modal screening approach helps detect cancer at a stage when it is curable. But in the rare event that a member is diagnosed at a late stage, our $1 million pledge ensures they receive the most advanced care available—without the burden of financial barriers.
How the $1 Million Pledge Works
Eligible individuals must be active pledge participants in HLI's Executive Health Program or affiliated Longevity Programs for pancreatic cancer early screening. These programs include:
Whole genome sequencing
Whole-body MRI, with dedicated pancreatic imaging
Long-term blood biomarker analysis
A DNA-based pancreatic cancer screening blood test
Qualified members diagnosed with late-stage pancreatic cancer while under HLI's care will receive up to $1 million toward treatment, care coordination, and access to a network of top-tier oncology experts from leading medical institutions.
Transforming the Future of Pancreatic Cancer Care
Pancreatic cancer is one of the deadliest forms of cancer due to its lack of early symptoms and late detection. Human Longevity's initiative aims to shift this paradigm by detecting disease earlier—when it is most treatable. The pledge not only offers support to individuals but also accelerates advancements in cancer screening technology through continuous real-world data integration and machine learning.
About Human Longevity, Inc.
Human Longevity, Inc. is a pioneering biotechnology company at the forefront of genomics, AI, and advanced medical technologies to extend healthspan and revolutionize preventative care. By leveraging vast genomic data, metabolomics, advanced imaging, and AI-driven diagnostics, Human Longevity is transforming healthcare from disease management to proactive prevention through its Executive Health and other Longevity Programs. The company remains committed to advancing medical research, improving patient outcomes, and unlocking the full potential of genomics to address the world's most pressing health challenges.
Media Contactmedia@humanlongevity.com
https://www.humanlongevity.com/1mpancreatic/
View original content to download multimedia:https://www.prnewswire.com/news-releases/human-longevity-inc-expands-pancreatic-cancer-prevention-commitment-with-1-million-pledge-for-qualified-members-302483622.html
SOURCE Human Longevity, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Marcelo Claure leads UK for-profit university deal in AI education push
Billionaire former SoftBank executive Marcelo Claure has led the purchase of a 50 per cent stake in one of the UK's largest for-profit Sign in to access your portfolio
Miami Herald
6 hours ago
- Miami Herald
Fed decision, jobs report will step out into spotlight
It's rare that folks think about a week of economic reports as potentially dramatic. This week, however, has the potential to be very dramatic. There's just so much data and, yes, politics, about to be loosed on markets, on businesses and around the world. Don't miss the move: Subscribe to TheStreet's free daily newsletter There's the July unemployment report, due Friday. The widely studied and analyzed PCE inflation report inflation report, due Thursday. There's the first round of estimates of second-quarter gross domestic product, the report card on how the economy is faring. Related: It's a lollapalooza week ahead for markets Parallel to the economic data are some 843 earnings reports due this coming week from the likes of Microsoft (MSFT) , Facebook-parent Meta Platforms (META) , Apple (AAPL) and (AMZN) . It all comes in the context of continued negotiations on trade deals with tariff rates coming in at lower rates than President Trump suggested in April. Trump said Sunday the European Union has agreed to a deal that envisions tariffs on European goods at 15%. The United States is still negotiating on tariffs with China, Canada and others. So far, stock investors are happy to get a settlement. Stock index futures were signaling stocks will open higher on Monday. Gains would come after the Standard & Poor's 500, Nasdaq Composite and Nasdaq-100 indexes all hit record highs last week. And, of course, there's the Federal Reserve meeting on Tuesday and Wednesday. Will the central bank cut its key federal funds rate, not at 4.25% to 4.5%? Donald Trump wants a rate cut badly now. Treasury Scott Bessent says he wants it. Howard Lutnick, the Commerce Secretary, says he wants it. Two Fed governors, Christopher Waller and Michelle Bowman, are for it. But the other 10 voting members of the Federal Open Market Committee, including Fed Chairman Jerome Powell, have said they're content to wait, probably until the Fed's Sept. 16-17 meeting. Related: Intel CEO outlines 'hard but necessary decisions'; Trader Guilfoyle: CEO Tan 'Has a Chance' Powell attracts most of President Trump's ire; he's threatened to fire Powell, whose term expires next May. (Whether he legally can fire Powell is not clear.) Powell remains worried the president's big beautiful tax bill and his tariffs will affect inflation. Powell is not opposed to cutting later and, in fact, the futures markets think the Fed will decide to wait until September. A second rate cut will come in October or December. Overnight trading in the 10-year Treasury note shows the yield rising to 4.41% from Friday's 4.392%. Related: Mexican restaurants, chains hit hard by Chapter 11 bankruptcy There are estimates showing jobs growth falling to around 110,00 from 147,000 in June with the unemployment rate holding at 4.1% or so. But this bit of data has become quite volatile and a bit suspect because it's getting harder to obtain reliable data from phone and online surveys. Bloomberg/Getty Images Another indicator should come Thursday when outplacement firm Challenger, Gray & Christmas should release its monthly tally of reported layoffs and job cuts. One more jobs indicator: the weekly report on initial jobless claims, due Thursday. The most recent report showed 217,000 layoffs, down 4,000 from a week earlier. More Tech Stocks: Analyst who correctly predicted Rocket Lab stock surge resets forecastVerizon Q2 earnings report surprises with remarks on tax reformFund manager who forecast Nvidia stock rally reboots outlook The Personal Consumption Expenditures Index measures what is happening to prices for services and products consumers actually buy. It was 2.3% year-over-year in June and may be up slightly in July. Related: Chapter 11 bankruptcy forces popular animal attractions to close Two reports will look at this question: the S&P Case-Shiller report that looks at home prices on Tuesday and the National Association of Realtors Pending Home Sales Index on Wednesday. The Case-Shiller report has suggested home prices are moderating. The pending sales report was up slightly in June but is down around 40% from levels last seen in 2022. Part of the downturn is due to: Higher interest home little construction of homes aimed at first-time home buyers. The Conference Board releases its Consumer Confidence Index report for July at 10 a.m. Tuesday. The University of Michigan releases its Consumer Sentiment Index at 10 a.m. Friday. Both look at how consumers are looking at inflation, the economy and other factors. The June reports showed increasing confidence, a reflection of better conditions in financial markets and the economy. Related: Veteran fund manager points to glaring stock market risk The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Business Insider
6 hours ago
- Business Insider
J.P. Morgan downgrades Bilibili, Inc. Class Z (9626) to a Hold
J.P. Morgan analyst downgraded Bilibili, Inc. Class Z to a Hold today and set a price target of HK$185.00. The company's shares closed last Friday at HK$184.80. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bilibili, Inc. Class Z with a HK$201.50 average price target. The company has a one-year high of HK$238.80 and a one-year low of HK$98.90. Currently, Bilibili, Inc. Class Z has an average volume of 5.21M.
